As Previously Announced, MedImmune to Provide
2003 Financial Results on January 29, 2004
GAITHERSBURG, Md., Jan. 23 /PRNewswire-FirstCall/ -- MedImmune, Inc.
(Nasdaq: MEDI) today announced that on March 1, 2004 it will hold a conference
call with investors to provide financial guidance for 2004, as well as insight
into its long-range plans for FluMist(TM) (Influenza Virus Vaccine Live,
Intranasal). Details for the March 1, 2004 conference call will be
distributed at a later date via press release and through the company's
website at www.medimmune.com.
David Mott, MedImmune's chief executive officer stated, "We currently
expect to complete our plans for FluMist with Wyeth, our co-promotion partner
for the vaccine, over the next several weeks, after which we can finalize our
2004 objectives. On March 1, we expect to be in a position to share our
financial guidance for 2004."
About MedImmune
MedImmune is a leading biotechnology company focused on researching,
developing and commercializing products to prevent or treat infectious
disease, autoimmune disease and cancer. MedImmune actively markets four
products, Synagis(R) (palivizumab), Ethyol(R) (amifostine), FluMist(TM)
(Influenza Virus Vaccine Live, Intranasal), and CytoGam(R) (cytomegalovirus
immune globulin intravenous (human)), and has additional products in clinical
testing. MedImmune employs approximately 1,800 people, is headquartered in
Gaithersburg, Maryland, and has additional operations in Frederick, Maryland,
as well as Pennsylvania, California, the United Kingdom and the Netherlands.
For more information on MedImmune and its products, visit the company's
website at www.medimmune.com.
DISCLOSURE NOTICE: This announcement may contain, in addition to
historical information, certain forward-looking statements that involve risks
and uncertainties. Such statements reflect management's current views and are
based on certain assumptions. Actual results could differ materially from
those currently anticipated as a result of a number of factors, including
risks and uncertainties discussed in the company's filings with the U.S.
Securities and Exchange Commission. The company is developing several products
for potential future marketing. There can be no assurance that such
development efforts will succeed, that such products will receive required
regulatory clearance or that, even if such regulatory clearance were received,
such products would ultimately achieve commercial success.
SOURCE MedImmune, Inc.
-0- 01/23/2004
/CONTACT: Investors & Media: Lori Weiman, +1-301-527-4321, Investors:
John Filler, +1-240-632-4086, or Media: Jamie Lacey, +1-240-632-4035, all of
MedImmune, Inc./
/Web site: http://www.medimmune.com/
(MEDI)
CO: MedImmune, Inc.
ST: Maryland
IN: BIO MTC
SU: ERP CCA
CD-MV
-- DCF036 --
9733 01/23/2004 12:40 EST http://www.prnewswire.com